[go: up one dir, main page]

AR054035A1 - Derivados benzodioxano y benzodioxolano y uso de los mismos - Google Patents

Derivados benzodioxano y benzodioxolano y uso de los mismos

Info

Publication number
AR054035A1
AR054035A1 ARP060101589A ARP060101589A AR054035A1 AR 054035 A1 AR054035 A1 AR 054035A1 AR P060101589 A ARP060101589 A AR P060101589A AR P060101589 A ARP060101589 A AR P060101589A AR 054035 A1 AR054035 A1 AR 054035A1
Authority
AR
Argentina
Prior art keywords
compounds
aliphatic
independently selected
hydrogen
sulfur
Prior art date
Application number
ARP060101589A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR054035A1 publication Critical patent/AR054035A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Se proveen compuestos que son agonistas o agonistas parciales del subtipo 12 o los receptores cerebrales de serotonina. Los compuestos, y las composiciones que contienen los compuestos, pueden usarse para tratar una variedad de desordenes del sistema nervioso central tal como esquizofrenia. Reivindicacion 1: Los compuestos de la formula (1) o una sal farmacéuticamente aceptable de éste donde m es 1 o 2; n es 0 o 1; Ar es fenilo, un anillo carbocíclico arilo o bicíclico parcialmente insaturado de 8-10 miembros, un heteroarilo monocíclico de 5-6 miembros que tiene 1-4 heteroátomos independientemente seleccionados entre nitrogeno, oxígeno o azufre, o un anillo heteroarilo o parcialmente insaturado bicíclico de 8-10 miembros que tiene 1-5 heteroátomos independientemente seleccionados de nitrogeno, oxígeno, o azufre, donde Ar está opcionalmente sustituido con uno o más grupos Rx; cada Rx está independientemente seleccionado de -R, Ph -CN, halogeno, -OP, y es 0-3; cada R1 es independientemente -R, -CN, halogeno, -OR, -C(O)NH2, -C(O)OR, -NHC(O)R, -SO2R o -NHSO2R; cada R es independientemente hidrogeno o alifático C1-6 o alifático C1-6 fluor-sustituido; R2 es hidrogeno, alquilo C1-3 o -O(alquilo C1-3); y cada uno de R3 y R4 es independientemente hidrogeno o alifático C1-6.
ARP060101589A 2005-04-22 2006-04-21 Derivados benzodioxano y benzodioxolano y uso de los mismos AR054035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67388405P 2005-04-22 2005-04-22

Publications (1)

Publication Number Publication Date
AR054035A1 true AR054035A1 (es) 2007-05-30

Family

ID=36688044

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101589A AR054035A1 (es) 2005-04-22 2006-04-21 Derivados benzodioxano y benzodioxolano y uso de los mismos

Country Status (20)

Country Link
US (1) US20060241172A1 (es)
EP (1) EP1871759A1 (es)
JP (1) JP2008538575A (es)
KR (1) KR20080009295A (es)
CN (1) CN101218223A (es)
AR (1) AR054035A1 (es)
AU (1) AU2006239930A1 (es)
BR (1) BRPI0610046A2 (es)
CA (1) CA2605580A1 (es)
CR (1) CR9459A (es)
GT (1) GT200600159A (es)
IL (1) IL186835A0 (es)
MX (1) MX2007013151A (es)
NI (1) NI200700270A (es)
NO (1) NO20075623L (es)
PE (1) PE20061335A1 (es)
RU (1) RU2007139543A (es)
TW (1) TW200720266A (es)
WO (1) WO2006116158A1 (es)
ZA (1) ZA200709043B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
US20060047001A1 (en) * 2004-08-24 2006-03-02 Parker Michael H Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
CN101189004A (zh) * 2005-04-22 2008-05-28 惠氏公司 疼痛的治疗
CN101198323A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防精神障碍的治疗组合
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
JP2008538571A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
TW200716595A (en) * 2005-04-22 2007-05-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
AU2006239920A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
WO2007112065A2 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
AR060493A1 (es) * 2006-04-18 2008-06-18 Wyeth Corp Derivados de benzodioxano y benzodioxolano. procesos de obtencion.
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
CL2007003065A1 (es) * 2006-10-24 2008-01-25 Wyeth Corp Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
WO2009021007A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
CA2722986A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
KR20100135325A (ko) * 2008-04-29 2010-12-24 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 조절제
US20110105462A1 (en) * 2008-04-29 2011-05-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
CA2724653A1 (en) 2008-05-21 2009-11-26 Ferring International Center S.A. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
EA018567B1 (ru) * 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103003246B (zh) 2010-07-20 2015-11-25 拜尔农科股份公司 作为抗真菌剂的苯并环烯烃
WO2012030953A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2012087289A1 (en) 2010-12-21 2012-06-28 Colgate-Palmolive Company Halogenated biphenols as antibacterial agents
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CA3029109A1 (en) * 2016-06-29 2018-01-04 Orion Corporation Benzodioxane derivatives and their pharmaceutical use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
WO2020086864A1 (en) * 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN109293480B (zh) * 2018-10-31 2020-10-09 陕西硕博电子材料有限公司 二烯丙基双酚a、制备方法及双马来酰亚胺树脂预聚物
WO2020212952A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
HUE064596T2 (hu) 2019-08-26 2024-03-28 Period Pill Bv Menstruációs ciklus által kiváltott tünetek kezelése
KR20230066313A (ko) 2020-06-08 2023-05-15 탁토젠 인크 정신 장애 또는 정신적 증강에 유리한 벤조푸란 조성물
CN112121463B (zh) * 2020-09-15 2022-03-22 烟台宁远药业有限公司 一种多取代苯并含氮杂环甲胺的制备方法
CN114890978B (zh) * 2022-04-19 2023-07-25 宿迁医美科技有限公司 酚类化合物及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906757A (en) * 1959-09-29 Their preparation
GB1054104A (es) * 1962-07-20
US3872105A (en) * 1973-06-11 1975-03-18 Merrell Inc Richard Derivatives of 1,3-benzodioxole-2-carboxylic acid
US4118507A (en) * 1977-03-17 1978-10-03 Shell Oil Company Benzodioxincarboxamide lipogenesis inhibitors
US5120758A (en) * 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
JP3454531B2 (ja) * 1991-11-07 2003-10-06 三共株式会社 ニトロキシアルキルアミド誘導体
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
FR2791675B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
GB0007376D0 (en) * 2000-03-28 2000-05-17 Knoll Ag Therapeutic agents
HRP20050044A2 (en) * 2002-07-29 2005-10-31 F. Hoffmann - La Roche Ag Novel benzodioxoles
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
CN100540546C (zh) * 2004-05-05 2009-09-16 弗·哈夫曼-拉罗切有限公司 用于调节5-ht6受体、5-ht2a受体或两者的芳基磺酰基苯并二烷
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
WO2006116148A2 (en) * 2005-04-22 2006-11-02 Wyeth (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
CN101198323A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防精神障碍的治疗组合
JP2008536946A (ja) * 2005-04-22 2008-09-11 ワイス うつ病の処置または予防のための新規の治療的組み合わせ
JP2008538571A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
CN101189004A (zh) * 2005-04-22 2008-05-28 惠氏公司 疼痛的治疗
AU2006239920A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
TW200716595A (en) * 2005-04-22 2007-05-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
CN101203218A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并呋喃基链烷胺衍生物和其作为5－ht2c激动剂的用途
JP2008538784A (ja) * 2005-04-24 2008-11-06 ワイス 膀胱機能を調節するための方法

Also Published As

Publication number Publication date
PE20061335A1 (es) 2006-12-29
KR20080009295A (ko) 2008-01-28
US20060241172A1 (en) 2006-10-26
BRPI0610046A2 (pt) 2010-05-25
CR9459A (es) 2008-02-20
AU2006239930A1 (en) 2006-11-02
TW200720266A (en) 2007-06-01
WO2006116158A1 (en) 2006-11-02
CN101218223A (zh) 2008-07-09
CA2605580A1 (en) 2006-11-02
IL186835A0 (en) 2008-02-09
NI200700270A (es) 2008-06-25
JP2008538575A (ja) 2008-10-30
NO20075623L (no) 2008-01-17
MX2007013151A (es) 2008-01-16
EP1871759A1 (en) 2008-01-02
RU2007139543A (ru) 2009-05-27
ZA200709043B (en) 2009-09-30
GT200600159A (es) 2007-03-14

Similar Documents

Publication Publication Date Title
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR106755A2 (es) Inhibidores pirrólicos de la proteína quinasa erk, síntesis e intermediarios de los mismos
ECSP066520A (es) Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso
AR056320A1 (es) Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR066583A1 (es) Derivados de 3,3-espiroindolinona
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR054799A1 (es) Derivados de oxindol
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
AR078786A1 (es) Derivados de la cromenona
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR042691A1 (es) Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas.
AR063374A1 (es) Derivados de benzoxazina y sus usos
AR088919A2 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y uso
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
AR049398A1 (es) Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados.
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure